Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2016-09-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2
different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when
administered at 4-week intervals for a total of 3 intravitreal injections in subjects with
neovascular age-related macular degeneration (AMD).